Am J Obstet Gynecol 196:268.e18
Add in consumer trends, like longevity and preventative health and biohacking, and all of a sudden we have a great market for peptides
These should definetely be approved for T1s The resistance to using GLP-1 RAs in type 1 diabetes can no longer be justified as a simple lack of indication. Studies such as Viral Shah et al
Compounded tirzepatide injections from licensed 503A pharmacies offer a meaningful alternative
Critically, these effects were achieved without food intake suppression, distinguishing MOTS-c from GLP-1 receptor agonists whose primary mechanism involves appetite reduction
Table 1 below presents a listing of compounds in Family 1 , drawn to mimetics, and Famillies 2-5, drawn to antagonists, all of which have been synthesized and analyzed according to the procedures described above